Exelixis Inc $4.14

up +0.10


29/8/2014 04:00 PM  |  NASDAQ : EXEL  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get EXEL Trend Analysis - it has underperformed the S&P 500 by 42%

Partner Headlines

  1. Mid-Afternoon Market Update: Harmonic Drops On Weak Forecast; URS Shares ...

    Benzinga
  2. Harmonic Drops On Weak Forecast; URS Shares Surge

    Benzinga
  3. Mid-Morning Market Update: Markets Open Higher; Citigroup Profit Beats ...

    Benzinga
  4. Morning Market Movers

    Benzinga
  5. Exelixis Shares Move 12% On Phase 3 Data

    Benzinga
  6. Benzinga's Top #PreMarket Gainers

    Benzinga
  7. Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

    Benzinga
  8. Benzinga's Top #PreMarket Gainers

    Benzinga
  9. Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, ...

    GuruFocus
  10. Market Wrap For March 26: Markets Close Near Session Lows In Yet Another ...

    Benzinga
  11. Mid-Afternoon Market Update: Markets Turn Red as Dish Network Rises

    Benzinga
  12. Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis Shares ...

    Benzinga
  13. Mid-Morning Market Update: Markets Open Higher; Francesca's Issues Downbeat ...

    Benzinga
  14. Stocks Hitting 52-Week Lows

    Benzinga
  15. Morning Market Losers

    Benzinga
  16. Benzinga's Top #PreMarket Losers

    Benzinga
  17. Morning Market Movers

    Benzinga
  18. US Stock Futures Rise Ahead Of Housing Data

    Benzinga
  19. Exelixis Prices 10M Share Offering at $8 per Share

    Benzinga
  20. Oversold ETFs Looking Attractive (IHE, CSD, PSCE)

    Benzinga
  21. Exelixis Announces Promising Phase 1b Data for Cobimetinib in Combination ...

    Benzinga
  22. US Stock Futures Rise Ahead Of Jobless Claims, GDP Data

    Benzinga
  23. Exelixis Announces Full Patient Enrollment for COMET-1 Phase 3 Trial

    Benzinga
  24. US Stock Futures Up After Upbeat China Data

    Benzinga
  25. Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib

    Benzinga
  26. Exelixis Receives EMA Acceptance of Marketing Authorization App for COMETRIQ

    Benzinga
  27. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  28. Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort in Metastatic ...

    Benzinga
  29. First Solar, Sears Holdings Among Stocks Down on Above-average Volume Thursday

    FoxBusiness
  30. Exelixis Says FDA Says NDA Has Been Removed from November Agenda

    Benzinga
  31. UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity Financing ...

    Benzinga
  32. Social Media Outlook for Thursday August 9 (EAT, NOV, NWSA, FSYS)

    Benzinga
  33. Exelixis, Universal Display Corporation Among Stocks Up on High Volume ...

    FoxBusiness
  34. FDA's Oncologic Drugs Advisory Committee to Review Exelixis New Drug Application ...

    Benzinga
  35. Exelixis (EXEL) Loses 8.8% As Company Sells Stock, Debt

    MarketIntelligenceCenter
  36. Health Care Sector Wrap

    FoxBusiness
  37. HCA Holdings, American Capital Mortgage Investment Crp Among Stocks Down ...

    FoxBusiness
  38. Interpublic Group, Exelixis Gapping Down Monday

    FoxBusiness
  39. UPDATE: Exelixis Announces Proposed Convertible Debt Offering of $225M; ...

    Benzinga
  40. Exelixis Proposed Offering 20M Shares

    Benzinga
  41. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  42. Social Media Outlook for Monday July 30 (SHAW, BBY, EXEL, VHC)

    Benzinga
  43. Benzinga's Top Pre-Market Gainers

    Benzinga
  44. FDA Grants Priority Review for Cabozantinib in Medullary Thyroid Cancer

    Benzinga
  45. Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored Trials ...

    Benzinga
  46. Jefferies Reiterates Hold Rating, $6 PT for Exelixis

    Benzinga
  47. Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue in Advanced ...

    Benzinga
  48. Cabozantinib Meets Primary Endpoint of Progression Free Survival in Phase ...

    Benzinga
  49. Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily Pretreated ...

    Benzinga
  50. Exelixis Completes Submission of New Drug Application for Cabozantinib ...

    Benzinga
Trading Center